Hikma appoints Rebecca Hall as CFO

Hikma names Rebecca Hall as CFO, bringing experience from ViiV Healthcare's £8bn revenue growth.

What the company is saying

Hikma Pharmaceuticals PLC has announced Rebecca Hall as its incoming Chief Financial Officer and Executive Director, with her start scheduled for Q1 2027 and the precise date to be confirmed. The company highlights Hall’s recent role as Senior Vice President and CFO at ViiV Healthcare, where she oversaw finance, supply chain, and business development, and where ViiV delivered close to £8 billion in revenue and 11% growth in 2025. The announcement emphasizes Hall’s more than twenty years of experience across GSK and ViiV, her international background spanning London, North America, and Asia Pacific, and her leadership in both commercial and supply chain finance. CEO Said Darwazah frames the appointment as adding financial and operational discipline to support Hikma’s strategic plans, while Chair Victoria Hull describes it as broadening the Board’s expertise for sustainable growth. Areb Kurdi will remain Acting CFO until Hall’s arrival, and Khalid Nabilsi will step down from the Board on 31 December 2026 but continue as Deputy CEO for North America and Europe. The tone is confident and forward-looking, with aspirational remarks from Hall about supporting Hikma’s growth ambitions and value creation.

What the data suggests

The announcement provides several concrete facts: Rebecca Hall will join Hikma as CFO and Executive Director in Q1 2027, with the exact date pending. Hall is currently Senior Vice President and CFO at ViiV Healthcare, which reported nearly £8 billion in revenue and 11% growth in 2025. Hikma itself employs 9,500 people globally, but no current financial or operational metrics for Hikma are disclosed. The succession plan is clearly outlined: Areb Kurdi continues as Acting CFO until Hall joins, and Khalid Nabilsi will step down from the Board at year-end but stay on as Deputy CEO. Hall’s career includes senior finance roles at GSK and ViiV, with international leadership experience in North America, Asia Pacific, Latin America, and MENA. The data confirms Hall’s credentials and the company’s orderly transition, but does not provide any direct evidence of Hikma’s current financial trajectory or performance. The only quantitative performance data relates to Hall’s prior employer, not Hikma.

Analysis

This announcement is a routine executive appointment notice, focused on the hiring of Rebecca Hall as CFO and Executive Director. The tone is positive, highlighting her experience and the succession plan, but does not overstate the impact or make exaggerated claims about future performance. The only forward-looking statements are procedural (her joining date to be confirmed) and aspirational (her enthusiasm for supporting growth ambitions), which are standard in such releases and not promotional. No financial or operational projections for Hikma are made, and there is no mention of capital outlay or immediate earnings impact. The numerical data provided relates solely to Rebecca Hall's prior employer, not Hikma itself, and serves only to establish her credentials. There is no gap between narrative and evidence, as the claims are factual and proportionate to the nature of the announcement.

Risk flags

• ●There is a transition risk as the CFO role will be held by an acting executive, Areb Kurdi, until Rebecca Hall’s arrival in Q1 2027. Prolonged interim periods can affect continuity in financial leadership and decision-making.
• ●Rebecca Hall’s effectiveness will depend on her ability to adapt from ViiV Healthcare’s specialist pharmaceutical environment to Hikma’s broader business and geographic scope. While her track record is strong, sector and company differences may present integration challenges.
• ●The announcement does not disclose Hikma’s own recent financial performance or strategic priorities, so investors have limited visibility into the immediate context Hall will inherit or the baseline against which her impact will be measured.

Bottom line

Hikma’s appointment of Rebecca Hall as CFO brings in a leader with a proven record at ViiV Healthcare, where she managed finance for a business generating close to £8 billion in revenue and achieving 11% growth in 2025. The transition plan is clear, with an acting CFO in place until Hall joins in Q1 2027, and the outgoing CFO, Khalid Nabilsi, remaining in a senior executive role. While Hall’s credentials are strong and her international experience is relevant, the announcement does not provide any new financial or operational data for Hikma itself, so investors cannot assess the current trajectory or the immediate challenges she will face. The most important takeaway is that Hikma is prioritizing experienced financial leadership, but the real test will be Hall’s ability to translate her prior success into value for Hikma once she assumes the role. Investors should watch for updates on her official start date and any early strategic signals after she joins.

Announcement summary

(LSE:HIK) Hikma Pharmaceuticals PLC announces the appointment of Rebecca Hall as Chief Financial Officer (CFO) and Executive Director. Rebecca Hall will join Hikma in Q1 2027, with the exact date to be confirmed in due course. She is currently Senior Vice President and Chief Financial Officer at ViiV Healthcare, where she is responsible for finance, supply chain, and business development. In 2025, ViiV Healthcare generated revenue of close to £8 billion and delivered 11% growth. Rebecca Hall has more than twenty years of experience at ViiV Healthcare and GSK, including roles in pharmaceuticals and consumer products. She has worked across three continents, including London, the US (where she led ViiV Finance for North America), and Singapore (where she led Supply Chain Finance for Asia Pacific, Latin America, and Middle East and North Africa). Said Darwazah, CEO of Hikma, welcomed Becky Hall and highlighted her financial and operational discipline. Areb Kurdi will continue as Acting CFO until Becky Hall joins. Victoria Hull, Chair of Hikma's Board of Directors, stated that Becky Hall's appointment broadens the expertise of the executive team and Board. Becky Hall expressed her enthusiasm for joining Hikma and supporting its growth ambitions. As Group CFO, Becky Hall will join the Board as an Executive Director, replacing Khalid Nabilsi, who will step down from the Board on 31 December 2026 but will continue as Deputy CEO, North America and Europe. Becky Hall began her career at GSK, progressing through various finance roles and serving as Chief of Staff to the GSK Group CFO. She joined ViiV Healthcare in 2018 as Global Finance Controller and Commercial Strategy Finance lead, later becoming Vice President and Head of North America Finance, and was appointed Senior Vice President and CFO of ViiV in 2024. She holds a BSc in Economics from the University of Durham and qualified as a CIMA accountant in 2007. Hikma confirms there is no further information required to be disclosed in relation to Rebecca Hall's appointment as a director pursuant to UK Listing Rule 6.4.8R. Hikma employs 9,500 colleagues globally.

Disagree with this article?